Eliem Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
CLYM$11.74+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-in · Accumulated Other Comprehensive · Accumulated · Total Stockholders’ | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Loss · Deficit · Equity | |||||||||
| Balance as of December 31, 2021 | 26,235,317 | $3 | $242,939 | $(123) | $(75,616) | $167,203 | |||
| Vesting of restricted stock awards | 154,869 | — | — | — | — | — | |||
| Stock-based compensation | — | — | 6,991 | — | — | 6,991 | |||
| Other comprehensive loss | — | — | — | (235) | — | (235) | |||
| Net loss | — | — | — | — | (45,244) | (45,244) | |||
| Balance as of December 31, 2022 | 26,390,186 | $3 | $249,930 | $(358) | $(120,860) | $128,715 | |||
| Vesting of restricted stock awards and units | 124,737 | — | — | — | — | — | |||
| Exercise of stock options | 1,111,512 | — | 841 | — | — | 841 | |||
| Stock-based compensation | — | — | 12,806 | — | — | 12,806 | |||
| Other comprehensive income | — | — | — | 356 | — | 356 | |||
| Net loss | — | — | — | (35,119) | (35,119) | ||||
| Balance as of December 31, 2023 | 27,626,435 | $3 | $263,577 | $(2) | $(155,979) | $107,599 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.